Pavan K. Vaddady
University of Tennessee Health Science Center
8 Papers
58 Citations
Pavan K. Vaddady is an academic researcher from University of Tennessee Health Science Center. The author has contributed to research in topics: Medicine & Pharmacodynamics. The author has an hindex of 4, co-authored 6 publications.
Chat about Author
Papers
In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB.
TL;DR: An introduction to in vitro PK/PD models and their application as critical tools in evaluating anti-TB drugs is provided and the related mathematical modeling approaches of time–kill data are discussed.
Dynamic time-kill curve characterization of spectinamide antibiotics 1445 and 1599 for the treatment of tuberculosis.
Pavan K. Vaddady,Ashit Trivedi,Chetan Rathi,Dora B. Madhura,Jiuyu Liu,Richard E. Lee,Bernd Meibohm +6 more
TL;DR: The PK/PD based analysis of the in vitro pharmacologic killing profile of spectinamides 1599 and 1445 on mycobacteria provided valuable insights that contributed to lead candidate selection and preclinical development of these compounds.
10
Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics of Protein Therapeutics
Pavan K. Vaddady,Bernd Meibohm +1 more
- 15 Apr 2010
TL;DR: The relevance of PK and PD affecting the efficacy, safety, and use of protein therapeutics is focused on, and different ways a protein molecule takes to reach its target tissue are explored.
2
Pharmacokinetics of a combination of Δ9‐Tetrahydro‐cannabinol and celecoxib in a porcine model of hemorrhagic shock
TL;DR: The concentration–time profiles of THC and CEL followed a multi‐exponential decline and their pharmacokinetics were similar in hemorrhagic shock and normotensive conditions, despite the substantial change in hemodynamics in the animals with shock.
2
A Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Insulin Dimer
Geoffrey A. Walford,Kelly Duncan,Moises Hernandez,Pavan K. Vaddady,Marcus Hompesch,Linda Morrow,S. Aubrey Stoch +6 more
TL;DR: MK‐1092 was well tolerated in all study populations, and no dose‐related adverse events were identified across the evaluated dose range (4–64 nmol/kg), and Circulating concentrations of MK‐ 1092 were approximately dose‐proportional.
1